Center for Fertility, Endocrine and Menopause

Patient Guide to Assisted Reproductive Technologies
# TABLE OF CONTENTS

## I. General Information

- Advanced Reproductive Technologies/Introduction .................................................. 3
- ART/IVF/Donor Egg Candidates ............................................................................. 3-4
- Getting Started ..................................................................................................... 4
- In Vitro Fertilization ............................................................................................... 4-9
  - Controlled Ovarian Stimulation and Monitoring .............................................. 6-7
  - Egg Retrieval .................................................................................................... 7
  - Fertilization ........................................................................................................ 7-8
  - Embryo Transfer ................................................................................................. 8
  - Luteal Phase Support ......................................................................................... 8
  - Pregnancy Test ................................................................................................... 9
- Risks Associated with IVF ...................................................................................... 9-10
- Additional ART Procedures .................................................................................... 10-13
  - Embryo/Oocyte Cryopreservation ................................................................... 10-11
  - Micromanipulation ............................................................................................ 11-13
    - ICSI (Intracytoplasmic Sperm Injection) ....................................................... 11-12
    - Assisted Hatching ......................................................................................... 11-12
  - Preimplantation Genetic Testing (PGT-A/PGT-M) ............................................ 12-13
  - Oocyte Donation ............................................................................................... 13-14

## II. Cycle Instructions

- Semen Specimen Collection .................................................................................... 15
- Daily Instructions for Your Cycle .......................................................................... 16
- Medications ........................................................................................................... 16-19
  - Gonadotropins/Subcutaneous Injections ......................................................... 16-18
  - Progesterone/Intramuscular Injections .............................................................. 18-19
- Pre-Retrieval Instructions ..................................................................................... 19
- Egg Retrieval ....................................................................................................... 20
- Embryo Transfer .................................................................................................. 20-22
  - Pregnancy Test ................................................................................................. 21-22
- Payment Policy ..................................................................................................... 23
- Important Phone Numbers .................................................................................... 24
Advanced Reproductive Technologies (ART) is a term used to describe a number of various techniques that have been developed to assist patients in becoming pregnant. These technologies include in vitro fertilization-embryo transfer (IVF-ET), frozen embryo transfer (FET), egg freezing, and micromanipulation. Micromanipulation refers to special techniques used by the ART laboratory to manipulate sperm, eggs, and/or embryos. These techniques include; intracytoplasmic sperm injection (ICSI), assisted hatching (AH), and preimplantation genetic testing (PGT).

This booklet is divided into two sections. Section I is a general review of the different ART technologies employed here at the Wake Forest Center for Fertility, Endocrine and Menopause (CFEM). Section II contains specific instructions related to the IVF cycle, as well a glossary. It is important that you read this booklet in its entirety and ask questions regarding any of the information presented.

ART/IVF CANDIDATES

Most patients who undergo ART have tried other less complex methods for treating their infertility. Although ART was originally developed to treat infertility caused by tubal disease or blockage, today it is an effective treatment for almost every cause of infertility. ART may be used as first-line therapy for patients with severe tubal disease, severe endometriosis, advanced age, or in couples with severe male factor infertility. It can also be used for patients who may be carriers of genetic disorders that may prevent them from having a healthy viable pregnancy, and couples who require donor sperm.

Prior to proceeding with ART all patients and partners should have completed a basic infertility evaluation. ART candidates who will be using their own eggs should be under 44 years of age and should have:

- No evidence of premature menopause
- At least one accessible ovary, and
- A normal uterus

All ART candidates should be in good health, have a normal uterus, and have no medical conditions that would pose a serious health risk to themselves or the child they would carry.

DONOR EGG CANDIDATES

Women desiring a pregnancy with donor eggs must have embryos created by the age of 49. To undergo an embryo transfer over the age of 44, the female must fulfill certain criteria, such as approval by MFM and satisfy appropriate cardiology and laboratory evaluation. If the female is
determined to be a good medical candidate, embryo transfers can be performed until her 55th birthday.

**GETTING STARTED**

Before proceeding with any ART cycle, all patients and their partners (if applicable) must have completed the following:

**Patient:**
1. A uterine evaluation within one year of ART cycle (sonohysterography or hysterosalpingogram).
2. An egg reserve test (AMH) within one year of ART cycle.
3. Infectious disease panel within one year of ART cycle including: Hepatitis B, Hepatitis C, HIV, Chlamydia/Gonorrhea, Syphilis, Blood Type, and Rubella immunity.
4. Additional lab work including Vitamin D and TSH testing
5. Weight loss, if needed, to achieve a BMI < 40
6. IVF payment/insurance verification through our financial counselor.

**Male Partner (if applicable):**
1. Infectious disease panel within one year of ART cycle including: Hepatitis B, Hepatitis C, HIV, Chlamydia/Gonorrhea, and Syphilis.
2. A semen analysis from an approved laboratory within the last year.
3. Optional freezing of back-up semen specimen.

Additionally, it is strongly recommended that all couples consider having recessive carrier screening completed to detect genetic abnormalities that may run in the family such as cystic fibrosis or sickle cell. This is not required, but is available.

Once the above tests have been completed, you and your partner (if applicable) will be scheduled for an appointment with the IVF Nurse Coordinator to learn about the medications, injection techniques, and review the consent forms.

**IN VITRO FERTILIZATION (IVF)**

In Vitro Fertilization is the process by which the female oocyte (egg) is allowed to be fertilized by the male sperm outside the human body. Once fertilization has taken place, the resulting embryo is transferred into the uterus (Embryo Transfer-ET) in order for implantation to occur. This technology has enabled many couples, who thought that pregnancy was impossible, to have children.
The first child born by this procedure was Louise Brown in 1978. Since that time, there has been a dramatic increase in the use and refinement of both in vitro fertilization (IVF) and embryo transfer, such that roughly 2% of all children born in the US are conceived through IVF. To date, there have been several million children born to couples who, without IVF-ET, had little or no hope of bearing children. IVF is well suited for patients who have damaged or no fallopian tubes, but it is also being used at most centers around the country for other causes of infertility (i.e., endometriosis, low sperm count and unexplained infertility).

Following the successful fertilization of the eggs in the laboratory, the embryo is placed back into the woman's uterus roughly 5 days after fertilization, or in a later month using a frozen-thawed embryo. Based on the success rates in established clinics in the United States, live birth rate per egg retrieval for non-donor cycles, is 54.5% for women under 35, but drops to 13.4% for women in their early 40’s. (Clinical Summary Report, SART, 2013).

**IVF-Fresh ET consists of the following steps:**

- A preparatory month using birth control pills, Lupron, Estrogen patches or a combination of these medications
- Ovarian stimulation using injectable gonadotropins specific to patient protocol
- Transvaginal ultrasound guided egg retrieval performed under anesthesia
- Fertilization of eggs in the laboratory using conventional insemination or Intracytoplasmic Sperm Injection (ICSI)
- Placement of fertilized eggs (embryos) into the uterus
- Luteal phase support with injectable progesterone
- Quantitative HCG pregnancy test
- Continued medication support with progesterone until 8 weeks gestation

**IVF-Frozen Embryo Transfer (FET) consists of the following steps:**

- Completion of an IVF cycle with embryos cryopreserved on day 5 of embryo development
- 2-3 weeks of estrogen priming using estrogen pills, patches or a combination of these medications
- Transvaginal ultrasound and blood work to determine endometrial thickness
- Injectable progesterone for endometrial receptivity and synchronization
- Placement of embryo into the uterus
- Quantitative HCG pregnancy test
- Continued medication support with estrogen and progesterone until 10 weeks gestation
1. CONTROLLED OVARIAN STIMULATION AND MONITORING

**Controlled Ovarian Stimulation (COS):**
Controlled Ovarian Stimulation is the term used for the stimulation of the ovaries to produce multiple eggs (follicles). The drugs used are all in the form of injection. Medications called gonadotropins will be used to stimulate the ovaries to produce multiple eggs. There are several gonadotropin products on the market today (see page 16 for a list of these medications). These drugs contain either the hormones FSH (Follicle Stimulating Hormone) and LH (Luteinizing Hormone) or FSH alone. These hormones are responsible for the production and maturation of eggs.

Additionally, one of two types of drugs will be used to prevent the premature release of eggs. Depending upon the stimulation protocol, Ganirelix®/Cetrotide® or in rare cases, Lupron®, will be incorporated in your daily injection regimen. Your nurse will provide you with instruction on when to start this medication.

The last medication prior to egg retrieval, called the “trigger shot”, is human chorionic gonadotropin (hCG) or Lupron in cases where there is concern for overproduction. This medication is used as a substitute for the midcycle hormonal surge which induces the final maturational changes in the eggs and prepares them for retrieval and fertilization. The trigger is administered when some of the follicles have reached appropriate size for retrieval (17-20mm).

**Our protocols are modified to meet the needs of each individual patient. Approximately 5% of patients will not develop enough eggs for retrieval and will need to be cancelled. These are typically patients with low AMH levels.**

**Timing of Egg Retrieval:**
The human egg is susceptible to fertilization for a short period of time. In IVF, it is important that the egg be at the right stage of development when it is exposed to sperm. Evidence of egg maturity is derived from both ultrasound measurements of follicle size and serum levels of estrogen (developing eggs produce estrogen). Once the eggs are at the appropriate size, hCG or Lupron will be given to trigger the final development of the egg. This is the last step in the egg maturation process. The trigger shot is given at night, and roughly 36 hours after the injection the eggs are ready for retrieval and subsequent fertilization. Therefore, women undergoing ovulation induction for IVF will be followed in two special ways, (ultrasound and estrogen measurements) to assess the development of the eggs in their ovaries.

**Ultrasound:**
A transvaginal ultrasound will give the physicians a visual description of the number of follicles developing, and the rate of development. Although one cannot visualize the egg by ultrasound,
one can visualize the fluid filled sac (follicle) in which the egg is growing. The maturity of the egg correlates to the size of the follicle. Unfortunately, the ultrasound cannot always distinguish between a cyst and a follicle containing an egg; thus the estrogen level is very important in helping the physician distinguish between the two.

A baseline ultrasound will be required prior to starting any stimulation medications. This is typically performed on day 2 of the menstrual cycle. Ultrasounds will then be performed every 2-3 days until egg retrieval. Most women need an average of 4-5 ultrasounds with each cycle.

**Estrogen Measurements:**
Estrogen measurements will also be used to follow the growth of the eggs. Because the growing follicles produce estrogen, measurement of serum estrogen is used to guide adjustments in your medication dosage and to give an estimate regarding egg maturity. The test to measure estrogen in blood takes several hours to run; for this reason, blood is drawn in the early morning so that the results will be ready in the afternoon. Estrogen measurements will be obtained on the days that an ultrasound is scheduled. Both the ultrasound and estrogen level will be used to determine the dose of medication and/or the timing of the trigger.

2. **EGG RETRIEVAL**

The egg retrieval is performed in the CFEM Minor Procedure Suite via transvaginal ultrasound guided aspiration. This method of egg retrieval is accomplished by inserting an ultrasound probe with a needle guide into the vagina. Anesthesia (conscious sedation) is required. Once the probe is lined up with the follicle (egg), the needle is advanced into the follicle and the fluid is removed. The probe is then redirected and the same method is employed until all follicles have been drained.

After the eggs are collected, they are taken to the lab adjoining the procedure room. While you are recovering from the procedure, the lab personnel will be identifying the eggs and preparing them for fertilization. You will receive an egg count at conclusion of the procedure.

3. **FERTILIZATION**

The contents of each follicle that is aspirated will be examined for an egg. Each egg will be graded as to its state of maturity and placed in a separate dish. The dish is then transferred to the incubator which provides an environment suitable for fertilization and development of an embryo. On the day of egg retrieval, a semen sample will be obtained. If conventional insemination is indicated, washed sperm will be placed alongside the egg in the dish. If intracytoplasmic sperm injection (ICSI) is used, a single sperm will be injected into each egg. This technique is necessary when the sperm count or motility is low. Depending on the quality of the sperm and eggs, one can expect 50%-70% of the eggs will fertilize. Cell division of the
fertilized egg will begin about 24-36 hours after retrieval. The embryologist will evaluate the embryo development and provide updates on the day after egg retrieval and again on day 6 of embryo development.

4. EMBRYO TRANSFER

If you are a candidate for a fresh transfer, your embryo will be ready for transfer on day 5 following egg retrieval. In cases of PGT or overstimulation, all embryos will be frozen and the embryo transfer will occur in a later month. The embryo transfer is an in-office procedure that does not require anesthesia.

Due to the complications of twins and higher order multiples, our goal is to create a singleton pregnancy. For PGT normal embryos, we highly recommend the transfer of only one embryo, and will transfer two embryos only in special circumstances. With the transfer of two genetically normal embryos, the twin rate approaches 80% and triplet rate is roughly 3%.

If embryos are not tested for genetics (PGT), we will allow the transfer of two embryos. However, in women under the age of 38 at the time of embryo creation, we still highly recommend the transfer of only one embryo due to the 40-45% twin rate with the transfer of two embryos. In women over 37, we will often transfer two embryos in order to maximize pregnancy rates.

Prior to the procedure, the embryologist and physician will meet with each couple to discuss the embryo quality, grading, and finalize the decision of how many embryos to transfer.

5. LUTEAL PHASE SUPPORT

Progesterone, which is produced by the ovary after ovulation, is important for fostering early conditions suitable for implantation of an embryo. Progesterone levels in IVF cycles are usually more than adequate because of the stimulation of the ovaries involved in the first part of the cycle. However, since the process of egg retrieval removes some of the cells that are responsible for making progesterone, it is important to supplement with progesterone following the egg retrieval. This supplementation will be in the form of progesterone injections. This medication will increase the levels of progesterone during the time of early pregnancy. Patients will stay on progesterone until the results of their pregnancy test are known. If a pregnancy has occurred, the progesterone will be continued for an additional 4 weeks.

During a frozen embryo transfer cycle, estrogen will be used to thicken your endometrium and prevent ovulation. Estrogen therapy will be used in conjunction with injectable progesterone until the results of the pregnancy test are known. If a pregnancy has occurred, estrogen and progesterone will be continued for an additional 6 weeks.
6. PREGNANCY TEST

Pregnancy tests are done 8-10 days following the embryo transfer. This blood level will be drawn in the morning and results will be called to the patient in the late afternoon of the same day. If this day falls on a weekend, the blood test will take place on the following business day.

**RISKS ASSOCIATED WITH IVF**

**Ovarian Hyper-Stimulation Syndrome:**

A rare complication of IVF is Ovarian Hyper-Stimulation Syndrome (OHSS). OHSS can occur when too many eggs are being developed in combination with a very high estrogen level. When eggs are aspirated from the ovary, hyper-stimulation is uncommon. In the rare event this does occur, symptoms may include pain, fluid accumulation into the abdomen, and alterations in electrolytes and circulation.

**Egg Retrieval:**

While rare, the risks of vaginal ultrasound retrieval include the possibility of bleeding, injury to internal organs, or infection which might require antibiotic treatment. You will be given prophylactic antibiotics just prior to the egg retrieval. Although adverse reactions are very rare, you will be monitored closely during and following the retrieval. There may be some discomfort with the procedure; however, you will be given IV sedation.

**Tubal Pregnancy:**

While rare, all ART procedures can result in an ectopic (tubal pregnancy). The rate of tubal pregnancy per embryo transfer is under 1%. All women with a positive pregnancy test will be followed carefully to facilitate early diagnosis of this condition.

**Additional Concerns:**

All couples who conceive naturally, have a 2%-5% risk of having a child with a birth defect. For years, data obtained from IVF centers across this country have not shown an increase in birth defects in children conceived from IVF techniques. More recent studies have shown around 4% of children conceived through IVF have some birth defect, many of which are minor. Other factors can contribute to birth defects such as advanced age of the mother and chromosomal abnormalities in the couple. IVF and associated techniques may also increase this risk; however, at this time there is limited evidence as to the role IVF has in increasing the risk of birth defects.
Roughly 18% of all pregnancies will result in a miscarriage, and roughly 1% of all pregnancies will end in a tubal pregnancy. However, if PGT is performed, the miscarriage rate drops to under 10%. While miscarriages often require no intervention, they occasionally need to be managed with a D&C (Dilation and Curettage). Tubal pregnancies can be life threatening, but if caught early, can be treated with a shot of methotrexate. If not diagnosed early, they must be removed, usually by laparoscopy.

There has been some concern regarding the use of ovulation induction agents and the development of ovarian cancer. More recent studies, however, have refuted the initial claims about such a link.

**Additional ART Procedures**

**EMBRYO/OOCYTE CRYOPRESERVATION**

In the early to mid 1990's the technique of freezing embryos was developed and refined. Today, embryo and oocyte cryopreservation is standard practice in many IVF centers. The current method of cryopreservation is vitrification, which is achieved by ultra-rapid cooling to quickly cryopreserve the embryo/oocyte in a suspended state. This process avoids ice crystallization and protects the embryos/oocytes from damage.

In embryo cryopreservation, eggs are fertilized with sperm and viable embryos are frozen on day 5 or 6 of development. If a patient does not become pregnant, or wishes to have another child, they can return to have the frozen embryos thawed and transferred without having to undergo ovarian stimulation and egg retrieval. This technology has increased the pregnancy rate for IVF by increasing the number of embryo transfers from one egg retrieval. The national live birth rate per transfer of thawed embryos is roughly 45% (*Clinical Summary Report, SART 2016*). This number increases if the embryos are genetically tested (PGT).

In recent years, many women have elected to preserve their fertility and delay childbearing by freezing their eggs at a young age. In oocyte cryopreservation, eggs are frozen for future fertilization. Patients who choose to proceed with egg freezing will undergo the same pretesting requirements and medication regimen as those undergoing IVF. Cryopreserved eggs are thought to be viable indefinitely once they are frozen.

Although embryo/oocyte cryopreservation is a good option for many women, not every patient will have embryos/oocytes to freeze. The decision to freeze viable eggs will be made on the day of egg retrieval. The decision to freeze viable embryos will be made on day 5 or 6 of embryo development, and will be determined by the embryologist. Some patients even elect to fertilize
only some eggs and freeze the remainder. This is helpful in women who want to minimize the number of embryos created.

**MICROMANIPULATION**

Advances in microscopic equipment and knowledge about eggs, sperm and embryos have led to the development of new techniques in ART. Micromanipulation refers to the handling and manipulation of individual eggs, sperm, or embryos in an effort to improve fertilization and/or pregnancy rates. These techniques require specialized equipment and personnel. Currently the most common micromanipulation techniques used are **Intracytoplasmic Sperm Injection (ICSI)** and **Assisted Hatching**. **ICSI** is used to assist fertilization in cases of male factor infertility as well as other diagnoses. **Assisted Hatching** is used to help the inner cell mass of the embryo “hatch” from the zona pellucida (outer shell). In addition, our facility also offers **Pre-Implantation Genetic Screening** in the form of chromosome abnormality screening (**PGT-A**) and single gene disorder screening (**PGT-M**). **PGT-A** is available for couples who wish to screen for chromosomal normalcy, knowing that most IVF failures and miscarriages are the result of a missing or extra chromosome. PGT-A also provides information on Trisomy 21 and gender. **PGT-M** is available for couples who have a genetic disorder that they do not wish to pass on to offspring, or which impairs their ability to maintain a pregnancy.

**Intracytoplasmic Sperm Injection (ICSI)**

The ICSI technique was developed in the early 1990’s to treat cases of severe male factor infertility. This technique involves injecting a single sperm into the interior (cytoplasm) of an egg. ICSI is not a guarantee of fertilization; however this intervention can overcome poor semen parameters.

Candidates for ICSI may include patients with very low sperm counts, poor motility, and/or abnormal morphology. This technique is also used in couples with a history of failed fertilization with conventional insemination. ICSI may also be used to achieve fertilization using surgically extracted sperm from patients with anatomic or surgical conditions (such as vasectomy) that prevent sperm from entering the ejaculate. We also use ICSI in other types of cases, such as unexplained infertility, diminished egg quality, low egg yield, and all PGT cases.

**Risks Associated with ICSI**

Recent evidence suggests that some forms of severe male factor infertility are genetic and may be passed on to male offspring through the ICSI procedure. In some studies, the incidence of congenital abnormalities (birth defects) following ICSI appears to 1%-2% higher than that of the general population.
Some risks associated with ICSI may include: possible genetic consequences of selecting an abnormal sperm for injection, degeneration of the egg caused by sperm injection, decreased fertilization rate, poor or arrested embryo development, and reduced chance of a successful pregnancy outcome. There is no guarantee that ICSI will result in either fertilization or pregnancy.

The alternatives to ICSI for treatment of severe male factor infertility are limited. One option is the use of donor sperm. Using donor sperm normalizes the success of conventional IVF-ET in couples with severe male factor infertility. In cases where male factor is the only diagnosis, pregnancies with donor sperm can be achieved through timed intrauterine insemination, a treatment far less expensive and complicated than IVF-ET.

**Assisted Hatching**

Assisted Hatching is a process wherein a special solution or a low-energy laser beam is used to dissolve the thick coating around the embryo. There is a small risk of damage to the embryos from the procedure. It is not clear which patients are the best candidates for assisted hatching. Currently, the laboratory uses Assisted Hatching on all Day 3 embryo transfers and all Frozen Embryo Transfers (non PGT-A/PGT-M embryos). In order to perform Assisted Hatching patients must sign a separate consent. Please note, assisted hatching is automatically done on all embryos undergoing genetic testing.

**Pre-Implantation Genetic Testing (PGT-A)**

Pre-Implantation Genetic Testing (PGT-A) is an IVF procedure designed to examine your embryos for chromosomal abnormalities, specifically the number of chromosomes. Most IVF failures and miscarriages are due to a missing or extra chromosome. Screening can potentially benefit all who present for IVF, particularly advanced maternal age couples and families who suffer with recurrent pregnancy loss. This procedure involves taking a biopsy from the trophectoderm (outer cell layer) of a Day 5 embryo (Blastocyst) and analyzing the genetic material chromosomal for abnormalities. Chromosomal abnormalities can result in aneuploidy (embryos having the wrong number of chromosomes). Typically, at least half of the embryos will carry an extra or missing chromosome, which is called aneuploidy. A higher percentage of abnormality is often found in women over the age of 35. PGT-A aims at improving pregnancy and live birth rates by allowing your physician to transfer only those embryos that are chromosomally normal.

**Pre-Implantation Genetic Testing (PGT-M)**

Pre-Implantation Genetic Testing (PGT-M) can be used in conjunction with IVF to screen embryos for genetic abnormalities. This procedure involves taking a biopsy from the
trophectoderm (outer cell layer) of a Day 5/6 embryo (Blastocyst) and analyzing the genetic material (DNA) for abnormalities. PGT-M is offered to patients who are carriers of single gene disorders (diseases that can be traced to a specific location on a gene).

Couples who wish to proceed with PGT-M testing will be referred to a genetics lab for registration and probe creation. You will be required to submit a cheek swab and DNA sample, which will be used to build a probe specifically designed for your family. When the probe is complete, the biopsied cells are analyzed to determine embryos that have inherited the disease and those embryos that are free from the disease. Please note that probe creation can take several months. Your IVF treatment cycle cannot start until probes are completed by the genetics lab.

**Risks Associated with PGT-A and PGT-M**

As in any conception, there is a risk of birth defects in children born following PGT-A/PGT-M testing. There is also the risk of a false negative result, which would lead to embryos being transferred that carry the disease in question. Additionally, it is possible that the test will find that there are no embryos suitable for transfer.

**PGT Follow up**

If you elect for PGT, the results often take 10-14 days to return to us. At that time, a phone consult will be arranged to review results with the physician.

**OOCYTE DONATION**

For some women pregnancy with their own eggs is highly unlikely. A few women carry a genetic defect which should not be passed on to their offspring; other women may not be able to produce good quality eggs. This may happen due to premature failure of the ovaries (early menopause), surgical removal of the ovaries, or failure of the ovaries to respond adequately to ovarian stimulation. Advancing age also affects and contributes to lower pregnancy rates and higher fetal defects in women over the age of 35.

Anonymous Frozen Egg Donation offers the opportunity for women to experience pregnancy and expand their families. Through third party anonymous Frozen Egg Donor Banks, prospective donors and intended parents are matched as closely as possible through selective profiles. The recipient couple will not have access to identifying information of their donor and conversely the donor will not have access to the identity of the couple receiving her eggs. The live birth rate per transfer is roughly 56.1 % (Clinical Summary Report; SART, 2013).
Steps involved in IVF with donor eggs include:

1) Identify donor agency and select anonymous donor
2) Third party coordinator will approve donor selection and coordinate shipment of frozen donor eggs to CFEM embryology lab
3) Consent forms, psychological screening, recessive carrier screening, and infectious disease screening
4) Thaw/Fertilization of donor eggs with designated sperm source
5) Uterine preparation with estrogen priming and progesterone per FET protocol
6) Transfer of the resulting embryo to the recipient's uterus
7) Pregnancy test 8-10 days later
8) Continuation of hormone support for an additional 6 weeks.

It is also important to consider the psychological aspects of using donated eggs. Many couples may have fears that a child conceived with donated eggs or sperm may not look like them or they may fear that they will not be able to bond to the child as they would a child conceived with their own eggs or sperm. Although these concerns are very common, they do need to be dealt with before proceeding with a Donor IVF cycle. If you are considering the use of donor eggs or sperm, you may be required to meet with a psychologist to discuss this option in detail and explore the psychological issues regarding donor gametes. Our center offers the services of a Reproductive Psychiatrist for couples in need of counseling.
INSTRUCTIONS FOR SEMEN SPECIMENS

A semen analysis is required in preparation for IVF. Results will determine the method of fertilization used in IVF. If your partner is providing a fresh sample, this will be collected on egg retrieval day. Please note that semen analysis is performed by appointment only. Please call the andrology lab at 336-716-3677 to schedule.

Below are instructions you should follow for each collection:

**IT IS IMPORTANT THAT YOU PROVIDE THE SPECIMEN AT THE DESIGNATED TIME. FAILURE TO DO SO MAY REQUIRE POSTPONEMENT OF YOUR IVF CYCLE.**

1. Please abstain from any ejaculation 2-5 days prior to your appointment. Abstinence for a longer or shorter period of time may affect the results. The preferred method of collection is by masturbation. Do not use a condom, and use only approved lubrication (Preseed) while obtaining the specimen. Most condoms contain a spermicide that will adversely affect semen quality.

2. The specimen may be collected at home or in the clinic collection room. If the specimen is collected at home, it must be in the office no more than one hour after collection. Specimens must be collected in a sterile container with a screw on lid. Keep the specimen between room and body temperature (70-98.6 degrees). All containers must be labeled with your name, partner’s name and time of collection.

3. Please bring a valid and current form of picture identification and insurance card with you at the time of your appointment for verification.
DAILY INSTRUCTIONS FOR YOUR CYCLE

The following pages contain information and instructions for you to follow in relation to your IVF cycle. You will find it helpful to review this material each time you enter a new phase of your cycle. Please refer to your specific protocol to see which information is pertinent to you.

You may also find it helpful to keep a calendar of clinic appointments. Please bring your workbook to your appointments so that we can make notes or changes if necessary.

MEDICATIONS

<table>
<thead>
<tr>
<th>Common Name</th>
<th>Actual Name</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ganirelix®</td>
<td>GnRH antagonist</td>
<td>To prevent spontaneous release of eggs</td>
</tr>
<tr>
<td>Cetrotide®</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lupron®</td>
<td>GnRH agonist</td>
<td>Ovarian suppression/prevent spontaneous release of eggs</td>
</tr>
<tr>
<td>Follistim®</td>
<td>Gonadotropins (FSH only)</td>
<td>Stimulate ovaries to develop multiple eggs</td>
</tr>
<tr>
<td>Gonal-F®</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Menopur®</td>
<td>Gonadotropins (FSH and LH)</td>
<td>Stimulate ovaries to develop multiple eggs</td>
</tr>
<tr>
<td>Novarel®</td>
<td>hCG</td>
<td>Final injection before egg retrieval, used to maturate eggs</td>
</tr>
<tr>
<td>Pregnyl®</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In addition to the information you will receive from us regarding your medications you may also access specific information on-line at the following website: www.freedommedteach.com

You will be required to attend a Medication Injection Teach class (scheduled by appointment only).

GONADOTROPINS (FSH, FSH/LH)

There are a variety of gonadotropins available for ovarian stimulation. You will be prescribed one or a combination of the following: Follistim®, Gonal-F®, and Menopur®. Gonadotropins are given to stimulate the ovaries to produce several follicles in one cycle. This allows the providers to retrieve more eggs and thus ensures a greater chance of fertilization.
Side Effects:
Side effects associated with these medications include injection site reactions and ovarian hyper-stimulation. Other reported side effects include dizziness, nausea, headaches, irritability and hot flashes. These, however, are thought to be associated with the increase in estrogen levels from the stimulated follicles.

Risks:
Hyper-stimulation of the ovaries is a potential risk when taking ovulation induction agents. Hyperstimulation occurs when the ovaries become enlarged. In mild to moderate cases of hyperstimulation, a person may experience abdominal distension and/or abdominal pain. Approximately 20% of patients will experience mild hyperstimulation. Symptoms usually resolve with the onset of menses, but in the case of pregnancy may continue for several weeks.

In severe hyper-stimulation (less than 1% of patients in IVF programs), ovarian enlargement is accompanied by accumulation of fluid in the abdomen, nausea, vomiting, weight gain and a decrease in urine output. Women who experience severe hyperstimulation require hospitalization.

If you notice any of the following symptoms, please call the IVF office immediately: weight gain of over 5 pounds from your baseline weight, a decrease in your urine output, severe abdominal pain, dizziness upon standing, nausea or other discomfort which you find concerning.

Subcutaneous Injections (Lupron®/Follistim®/Gonal-F®/Menopur®, hCG (Novarel®, Pregnyl®):

1. Select the site for administration (Figure 3).
2. Gently wipe the site with alcohol pad.
3. Tightly hold the medication-filled syringe and remove cap if necessary, being careful not to touch needle.
4. Hold syringe with needle pointing up and gently tap the syringe to move any air bubbles to the top of syringe.
5. If there is air in the top of the syringe, gently push the plunger up to remove air. Stop pushing the plunger when you no longer see air in the syringe.
6. Hold syringe with your dominant hand close to the base of the needle (hold syringe like a dart).
7. With the other hand, gently grasp a fold of skin at the injection site between your thumb and index finger (Figure 4).
8. Quickly insert needle into the fold of the skin all the way to the base of the needle.
9. Slowly push plunger to inject all of the contents in the syringe.
10. Withdraw needle and place in sharps container.
11. If there is any bleeding at the injection site, place a dry cotton ball or bandage over site and apply gentle pressure for 1-5 minutes.

Intramuscular Injections (Progesterone):

**Drawing up the medication:**

1. Wash your hands
2. Flip off plastic lid or metal tab on top of vial. Wipe the rubber stopper with an alcohol swab. This will be a multiuse vial with enough medication for 10 days. DO NOT REFRIGERATE
3. Use a 3 cc syringe with an 18-gauge, 1 ½ inch needle
4. Insert needle into the rubber stopper. Keep needle in the vial, turn vial upside down, keeping the needle below the fluid level and pull back on plunger, withdrawing 1 cc of liquid (liquid fills slowly). Flick syringe with finger to force air to surface, then push up plunger to expel air.
5. After drawing up the medication, change to the 22 gauge 1 ½ inch needle for injection.
6. Follow instructions for intramuscular injection.

**Injecting the medication:**

1. Cleanse the injection site with alcohol. Wait a few seconds until alcohol has dried on skin. Remove cap from needle.
2. Spread the skin, and insert the needle at a 90-degree angle into the skin as far as it will go.
3. Anchor the syringe with your free hand. Pull back slightly on the plunger; if you see blood return, remove the needle and re-inject in an alternate site.
4. If there is no blood return, inject medication slowly.
5. Withdraw the needle at the same angle at which it was inserted. Apply pressure at the injection site with gauze or tissue.
6. Dispose of used needle and syringes carefully in an approved sharps container.
7. Alternate sides with each daily injection.
8. Massage the injection site and use a heating pad for 20 minutes after the injection to help with absorption into the muscle.

PRE-RETRIEVAL INSTRUCTIONS

You will be scheduled for egg retrieval approximately 36 hours after your trigger injection. Egg retrieval will take place in the morning, and it is imperative that you arrive at your designated time so as not to delay the start of your procedures or those who may come after you. You will be told by our staff at what time to report to the CFEM Minor Surgical Procedure Suite. Below are instructions to follow prior to your retrieval.

The night before egg retrieval:

1. Eat a good supper and have a late night snack
2. Abstain from intercourse
3. Do not eat or drink anything after midnight.

The morning of egg retrieval:

1. Remove any make-up, hair pins, jewelry, or contact lenses
2. No perfume (deodorant is ok)
3. Do not eat or drink anything after midnight
4. Arrive in the CFEM Minor Procedure Suite at the designated time
THE DAY OF EGG RETRIEVAL

On the day of egg retrieval you will be asked to report to the CFEM Minor Procedure Suite. You will be given a place to store your clothing. The nurse anesthetist will talk with you and discuss your sedation at that time. An IV will also be placed in your arm, and pre-operative vital signs will be taken. The lab will tell your partner where and when to go to collect his semen specimen, if using fresh semen.

Once all the pre-operative work has been completed, you will be wheeled to the procedure room and transferred to the procedure table. The nurse anesthetist will begin to administer your sedation. You will be breathing on your own throughout the procedure, and may require supplemental oxygen. You will be draped with sterile sheets and towels. The doctor will then clean your vagina with a sterile solution.

Once the vagina has been thoroughly cleaned, the doctor will insert the vaginal ultrasound probe. Your doctor will then proceed to aspirate the follicles (fluid filled sacs containing the eggs). Lab personnel will be present for identification of the eggs. After all the follicles have been drained, the nurse anesthetist will begin to withdraw your sedation.

You will then be transferred to the recovery room where you will stay for approximately 30 minutes. You must be accompanied by an adult over the age of 18 in order to be discharged. Your physician will meet with you before you are discharged to review your post-operative instructions and precautions.

After Your Egg Retrieval
Following the egg retrieval, you may experience some abdominal soreness, vaginal spotting, nausea and/or vomiting. These symptoms should resolve within a couple of days. However, you should call the doctor if you experience excessive bleeding, difficulty breathing, severe pain, dizziness, or develop a fever. You may take Tylenol as needed for pain relief. If you are a candidate for a fresh embryo transfer, DO NOT TAKE Ibuprofen/Aleve/Motrin. If you are planning to freeze your embryos and proceed with an FET in a subsequent month, you can use Ibuprofen/Aleve/Motrin products as needed.

EMBRYO TRANSFER

The embryologist will call the day after your egg retrieval to discuss your fertilization results. If you are a candidate for a fresh transfer, this will take place 5 days after egg retrieval. This decision will be determined by the lab director and your physician. If you are not a candidate
for a fresh transfer, or you are planning for PGT, you will receive an update on day 6 of embryo development regarding embryo biopsy and embryo cryopreservation.

The Embryo Transfer does not require anesthesia. The procedure will be performed under ultrasound guidance with a full bladder. One hour before the procedure you should urinate to empty the bladder; then drink 24 ounces of fluids within 15-20 minutes to re-fill your bladder.

Prior to transfer, you will meet with the physician and embryologist to review embryo grading, quality and finalize the plan for embryo transfer. You will be escorted to the procedure room, asked to undress from the waist down, and draped with a sheet. The transfer will be performed using sterile procedure. The physician will place a speculum in the vagina. The vagina and cervix will be thoroughly cleansed before transferring the embryo(s). An abdominal probe will be placed on the abdomen so that the uterus can be visualized. The embryo(s) will be transferred into your uterine cavity via a catheter guided through your cervix.

You may feel some mild cramping during the transfer; however this should resolve once the catheter is removed. After the embryo(s) is transferred you will be asked to rest on the exam table for approximately 10-15 minutes.

Implantation Support

After the transfer, there are several things you can do to help the embryo have the best possible chance of implanting. The first is to continue any medications that you have been prescribed that support the uterine lining and help to maintain a pregnancy. These medications (which may include, but are not limited to Progesterone, Estrogen Pills, Estrogen Patches, and Aspirin) will be taken until the pregnancy test. If your pregnancy test is positive, you will continue all medications until 8-10 weeks gestation. It is recommended to continue prenatal vitamins. If you were instructed to take baby aspirin with your cycle, you should be prepared to continue until your OB/GYN advises you to stop.

Additionally, you'll be asked to do "couch rest" after the embryo transfer - take the day off, put your feet up and rest as much as possible (it is fine for you to walk and ride in a car). After the first 24 hours, patients should continue to take it easy for an additional three or four days. You can go back to work and lead your normal life, but strenuous exercise, chores, and even sexual relations should be avoided. Anything that causes uterine contractions could affect the implantation process.

Pregnancy Test

Your quantitative hCG “pregnancy test” will be scheduled 8 days after your day 5 transfer, or 10 days after your day 3 transfer. Please note that these tests are not done on the weekends.

As tempting as it is, fertility patients are advised not to use home pregnancy tests. Home pregnancy tests can render false results for fertility patients, either negative or positive. A false positive can result because hCG is given to “trigger” ovulation and may remain in the blood and
a home pregnancy test cannot determine the difference between the two. A false negative might occur because a low level of hCG may be undetectable in a urine test despite a pregnancy starting.

**When the Test is Positive**

If your pregnancy test is positive, your doctor or nurse will tell you the hCG level that your test showed. The test result is stated as a number that indicates the level of hCG found in the blood. This number will increase fairly rapidly in healthy pregnancies, so multiple pregnancy tests will be ordered over the next several days to confirm the pregnancy is developing normally.

A blood hCG level over 50 is a good first result but many, many ongoing pregnancies start out with an hCG level below that number. You'll be asked to repeat the test in 2 to 4 days. The goal is to watch the trend of your hCG to confirm that it is rising appropriately.

If both blood tests indicate a healthy pregnancy, then a vaginal ultrasound will be scheduled between 7-8 weeks gestation. At that time, your doctor will be looking for a gestational sac and fetal heart tones to confirm the pregnancy.

Most patients will continue to take hormone medications throughout this 8-10 week period to support the developing pregnancy. After a good confirmatory ultrasound at 7-8 weeks gestation, you will be released back to your regular OB/GYN to begin normal prenatal care.

**If the Results are Negative**

If you get a negative result on your pregnancy test, it's very disappointing. It's important to remember that you have a treatment plan with options for trying again. We will support you in every way we can.

We will start by instructing you to stop your medications and schedule a consultation with your doctor. At that time, you will discuss the details of your cycle, how you want to proceed, and any changes you might make to your protocol.

Some patients may start a new IVF cycle or FET cycle on their next menstrual cycle while others may have to wait a month or two longer. Patients should remember that not everyone is successful on their first cycle but that doesn't mean that success in subsequent attempts is impossible.
PAYMENT POLICY

IVF can be an expensive endeavor especially if you do not have insurance coverage. We make every effort to keep the IVF and associated procedures affordable options for infertility patients.

It has been the policy of Wake Forest University Physicians and North Carolina Baptist Hospital to require payment of elective procedures and therapies prior to the initiation of treatment. If you have insurance coverage for IVF, you may be asked to pay the portion your insurance does not cover before initiating treatment.

All couples are asked to call Patty Joyner, the Financial Counselor, to discuss payment of your IVF cycle. If you do not have insurance coverage for IVF, you will be asked to pay the cost of the cycle prior to beginning the stimulation medications. Patty Joyner will assist you with this process.
### IMPORTANT PHONE NUMBERS

<table>
<thead>
<tr>
<th>Service</th>
<th>Phone Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wake Forest Center for Fertility, Endocrine and Menopause</td>
<td>(P) 336-716-6476 (F) 336-716-0194</td>
</tr>
<tr>
<td>- Office hours are 8:00am-5pm</td>
<td></td>
</tr>
<tr>
<td>- Telephone hours are 8:30am-4:00pm, closed 12noon-1:00pm for lunch</td>
<td></td>
</tr>
<tr>
<td>ART/Andrology Lab</td>
<td>336-716-3677</td>
</tr>
<tr>
<td>Emergencies: after 5:00 p.m., weekends, and holidays (have the operator page the doctor on call for The Center for Reproductive Medicine)</td>
<td>336-716-2011</td>
</tr>
<tr>
<td>Roxanne Kennedy, RN, BSN, IVF Coordinator</td>
<td>336-716-6476</td>
</tr>
<tr>
<td>Chelsea Kiser, RN, Third Party Coordinator</td>
<td>336-716-6476</td>
</tr>
<tr>
<td>Financial Counselor (Patty Joyner)</td>
<td>336-716-1269</td>
</tr>
</tbody>
</table>